Showing results (111-120 of 150) with videos related to
Sort By:
Pageof 15
Thoracic Cancer|January 11, 2019
Survival comparison of right and left side non-small cell lung cancer in stage I-IIIA patients: A Surveillance Epidemiology and End Results (SEER) analysisBo Jia, Qiwen Zheng, Xinmeng Qi, et al.Thoracic Cancer|September 29, 2018
Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study)Yan Xu, Li Zhang, Jian Fang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2024
Efficacy and Safety of Taletrectinib in Chinese Patients With <i>ROS1+</i> Non-Small Cell Lung Cancer: The Phase II TRUST-I StudyWei Li, Anwen Xiong, Nong Yang, et al.Immunotherapy|July 19, 2023
Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in AsiaYing Cheng, James Chih-Hsin Yang, Isamu Okamoto, et al.Thoracic Cancer|December 16, 2021
Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lungYuan Feng, Wei Sun, Jie Zhang, et al.Targeted Oncology|September 4, 2024
A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or LymphomaJifang Gong, Ye Guo, Yanqiao Zhang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 2, 2022
Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled TrialCaicun Zhou, Dingzhi Huang, Yun Fan, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2021
Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 StudyXinghao Ai, Qiming Wang, Ying Cheng, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy AloneFei Zhou, Jiao Zhang, Shengxiang Ren, et al.Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|April 25, 2021
[Chinese Experts Consensus on Immune Checkpoint Inhibitors
for Non-small Cell Lung Cancer (2020 Version)]Caicun Zhou, Jie Wang, Baocheng Wang, et al.Pageof 15